Paul P. Kaijen

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Trp1250, Lys1252, and Arg1367 of ADAMTS13 comprise a hot spot for anti-CUB domain antibodies in patients with iTTP.

Trp1250, Lys1252, and Arg1367 of ADAMTS13 comprise a hot spot for anti-CUB domain antibodies in patients with iTTP.

Journal: Blood advances
Published: May 19, 2025

Sustained high expression of human FVII following AAV8-mediated gene delivery in mice.

Sustained high expression of human FVII following AAV8-mediated gene delivery in mice.

Journal: Molecular therapy. Methods & clinical development
Published: December 27, 2024

N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP.

N-glycan shielded CUB domains of ADAMTS13 prevent binding of C-terminal antibodies in patients with immune-mediated TTP.

Journal: Blood advances
Published: July 22, 2024

FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4.

FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4.

Journal: Haematologica
Published: July 03, 2024

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.

The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.

Journal: Frontiers in immunology
Published: December 14, 2023

N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP.

N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP.

Journal: Blood
Published: July 01, 2020

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.

Journal: Haematologica
Published: November 21, 2019

Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.

Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ.

Journal: Haematologica
Published: August 21, 2017

The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages.

The class I scavenger receptor CD163 promotes internalization of ADAMTS13 by macrophages.

Journal: Blood advances
Published: September 12, 2016

Identification of glycans on plasma-derived ADAMTS13.

Identification of glycans on plasma-derived ADAMTS13.

Journal: Blood
Published: June 06, 2016

CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides.

CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides.

Journal: Blood
Published: October 02, 2015

Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.

Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice.

Journal: Blood
Published: April 14, 2012
Showing 1-12 of 12

Last Updated: 09/26/2026